白细胞减少症 中国就医指南

Leukopenia is a hematologic condition characterized by an abnormally low absolute white blood cell (WBC) count—typically defined as fewer than 4,000 leukocytes per microliter (μL) of peripheral blood. It is not a disease in itself but rather a laboratory finding reflecting underlying dysfunction in bone marrow production, increased peripheral destruction, or abnormal sequestration of white blood cells. The most clinically significant subtype involves neutropenia (absolute neutrophil count <1,500/μL), as neutrophils constitute the primary defense against bacterial and fungal infections. Pathogenesis varies widely: it may stem from bone marrow suppression (e.g., due to chemotherapy, radiation, or aplastic anemia), autoimmune destruction (e.g., systemic lupus erythematosus), viral infections (e.g., HIV, hepatitis, EBV), nutritional deficiencies (e.g., severe vitamin B12 or folate deficiency), hypersplenism, or drug-induced toxicity (e.g., antithyroid agents, sulfonamides, clozapine). Inherited forms—such as Kostmann syndrome or cyclic neutropenia—are rare but important in pediatric populations. Epidemiologically, leukopenia is common in clinical practice: prevalence rises with age and comorbidity burden. Among hospitalized adults in China, studies estimate incidence at 5–12% depending on setting—higher in oncology, ICU, and geriatric units. Risk factors include advanced age (>65 years), chronic inflammatory or autoimmune diseases, active malignancy (especially hematologic cancers), prolonged use of myelosuppressive medications, HIV infection, alcohol use disorder, and exposure to benzene or ionizing radiation. Importantly, asymptomatic mild leukopenia may be incidental and benign; however, moderate-to-severe cases significantly increase susceptibility to recurrent or life-threatening infections—including pneumonia, cellulitis, sepsis, and oral mucositis—which impair daily functioning, delay cancer therapy, reduce work capacity, and diminish overall quality of life. Patients often report fatigue, fever of unknown origin, sore throat, gingival ulcers, and recurrent skin infections. Psychological impacts—including anxiety about infection risk and treatment interruptions—further erode mental well-being and social engagement. Early diagnosis requires comprehensive evaluation: complete blood count with differential, peripheral blood smear, bone marrow aspiration/biopsy when indicated, serologic testing for autoimmunity or infection, and review of medication history. Without timely intervention, persistent leukopenia can lead to treatment delays in curative regimens (e.g., chemotherapy cycles), increased hospitalization rates, and higher mortality in immunocompromised cohorts. Management must therefore be individualized—not only to correct the WBC count but also to address root causes, prevent complications, and support long-term hematopoietic recovery.

# 白细胞减少症治疗方案与费用明细（血液科）

一、非手术/保守治疗方案

适用人群：轻中度（ANC ≥1.0×10⁹/L）、病因明确且可逆者（如药物性、营养缺乏、轻度自身免疫）

• •基础支持：维生素B₁₂/叶酸补充、停用可疑药物、感染防控指导

• •促白细胞生成药物（G-CSF类）：

- 长效（如聚乙二醇化rhG-CSF）：2,800–4,200元/支，单次皮下注射，每14天1次

• •免疫调节治疗（用于自身免疫性）：泼尼松+硫唑嘌呤方案

二、手术/介入治疗方案

注：白细胞减少症本身无手术指征；仅当合并需造血干细胞移植的原发病（如再生障碍性贫血、MDS高危型）时启动

• •异基因造血干细胞移植（allo-HSCT）：适用于重度难治性、进展为骨髓衰竭或克隆性疾病者

- 全套移植费用（含预处理、供者动员采集、回输、住院支持治疗）：35万–65万元（医保报销后自付约8–22万元）

三、特殊复杂情况方案

• •化疗相关重度中性粒细胞缺乏（ANC＜0.5×10⁹/L伴发热）：需住院+广谱抗生素+G-CSF+真菌预防

• •继发于淋巴瘤/白血病者：按原发病方案治疗，白细胞恢复为疗效指标之一

方案快速选择指南

✅ 预算有限/初诊轻症：首选保守治疗+G-CSF（总费用≤5,000元） ✅ 反复感染/中重度（ANC＜1.0）：启动免疫调节+骨髓活检，预算1.2–2万元 ✅ 难治性/进展性骨髓衰竭：评估allo-HSCT，建议三甲血液中心多学科会诊